Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective To evaluate quinidine as a precision therapy for severe epilepsy due to gain of function mutations in the potassium channel gene KCNT1. Methods A single-center, inpatient, order-randomized, blinded, placebo-controlled, crossover trial of oral quinidine included 6 patients with severe autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) due to KCNT1 mutation. Order was block randomized and blinded. Four-day treatment blocks were used with a 2-day washout between. Dose started at 900 mg over 3 divided doses then, in subsequent participants, was reduced to 600 mg, then 300 mg. Primary outcome was seizure frequency measured on continuous video-EEG in those completing the trial. Results Prolonged QT interval occurred in the first 2 patients at doses of 900 and 600 mg quinidine per day, respectively, despite serum quinidine levels well below the therapeutic range (0.61 and 0.51 μg/mL, reference range 1.3–5.0 μg/mL). Four patients completed treatment with 300 mg/d without adverse events. Patients completing the trial had very frequent seizures (mean 14 per day, SD 7, median 13, interquartile range 10–18). Seizures per day were nonsignificantly increased by quinidine (median 2, 95% confidence interval −1.5 to +5, p = 0.15) and no patient had a 50% seizure reduction. Conclusion Quinidine did not show efficacy in adults and teenagers with ADNFLE. Dose-limiting cardiac side effects were observed even in the presence of low measured serum quinidine levels. Although small, this trial suggests use of quinidine in ADNFLE is likely to be ineffective coupled with considerable cardiac risks. Clinical trials registration Australian Therapeutic Goods Administration Clinical Trial Registry (trial number 2015/0151). Classification of evidence This study provides Class II evidence that for persons with severe epilepsy due to gain of function mutations in the potassium channel gene KCNT1, quinidine does not significantly reduce seizure frequency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barcia, G., Fleming, M. R., Deligniere, A., Gazula, V.-R., Brown, M. R., Langouet, M., Chen, H., Kronengold, J., Abhyankar, A., Cilio, R., et al. (2012) · Nature Genetics · doi:10.1038/ng.2441 · Cited by 525 · cited 1×
“An even more devastating epileptic encephalopathy, epilepsy of infancy with migrating focal seizures (EIMFS), is caused byKCNT1mutations, typically arising de novo.(3) EIMFS has a poor prognosis with profound developmental impairment and high mortality.”
BackgroundHeron, S. E., Smith, K. R., Bahlo, M., Nobili, L., Kahana, E., Licchetta, L., Oliver, K. L., Mazarib, A., Afawi, Z., Korczyn, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2440 · Cited by 411
Self-citationPrevention of atrial fibrillation after cardioversion: results of the PAFAC trial
FETSCH, T. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.04.015 · Cited by 334
McTague, A., Appleton, R., Avula, S., Cross, J. H., King, M. D., Jacques, T. S., Bhate, S., Cronin, A., Curran, A., Desurkar, A., et al. (2013) · Brain · doi:10.1093/brain/awt073 · Cited by 170
Self-citationSuppression of paroxysmal atrial tachyarrhythmias—results of the SOPAT trial
PATTEN, M., MAAS, R., BAUER, P., LUDERITZ, B., SONNTAG, F., DLUZNIEWSKI, M., HATALA, R., OPOLSKI, G., MULLER, H., & MEINERTZ, T. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.014 · Cited by 157
Glucose Transporter 1 Deficiency as a Treatable Cause of Myoclonic Astatic Epilepsy
Mullen, S. A., Marini, C., Suls, A., Mei, D., Della Giustina, E., Buti, D., Arsov, T., Damiano, J., Lawrence, K., De Jonghe, P., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.102 · Cited by 138
Self-citation
Cited by
Devinsky, O., Vezzani, A., O'Brien, T. J., Jette, N., Scheffer, I. E., de Curtis, M., & Perucca, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.24 · Cited by 959
Self-citationSymonds, J. D., Zuberi, S. M., Stewart, K., McLellan, A., O‘Regan, M., MacLeod, S., Jollands, A., Joss, S., Kirkpatrick, M., Brunklaus, A., et al. (2019) · Brain · doi:10.1093/brain/awz195 · Cited by 459
Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies
Oyrer, J., Maljevic, S., Scheffer, I. E., Berkovic, S. F., Petrou, S., & Reid, C. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014456 · Cited by 315
Self-citationDevelopmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
Self-citationAntisense oligonucleotide therapy for KCNT1 encephalopathy
Burbano, L. E., Li, M., Jancovski, N., Jafar-Nejad, P., Richards, K., Sedo, A., Soriano, A., Rollo, B., Jia, L., Gazina, E. V., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.146090 · Cited by 80
Self-citation
Metadata
- Authors
- Mullen, S. A., Carney, P. W., Roten, A., Ching, M., Lightfoot, P. A., Churilov, L., Nair, U., Li, M., Berkovic, S. F., Petrou, S., & Scheffer, I. E.
- Venue
- Neurology
- Published
- 2018-01-02
- Volume
- 90
- Issue
- 1
- Pages
- e67-e72
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2775120542
- Cited by
- 147
- References
- 6
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine. https://app.cochat.ai/papers/10.1212/wnl.0000000000004769
- The paper
- Mullen, S. A., Carney, P. W., Roten, A., Ching, M., Lightfoot, P. A., Churilov, L., Nair, U., Li, M., Berkovic, S. F., Petrou, S., & Scheffer, I. E. (2018). Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine. Neurology. https://doi.org/10.1212/wnl.0000000000004769
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.